Exploring macrophage cell therapy on Diabetic Kidney Disease.
J Cell Mol Med
; 23(2): 841-851, 2019 02.
Article
em En
| MEDLINE
| ID: mdl-30407737
ABSTRACT
Alternatively activated macrophages (M2) have regenerative properties and shown promise as cell therapy in chronic kidney disease. However, M2 plasticity is one of the major hurdles to overcome. Our previous studies showed that genetically modified macrophages stabilized by neutrophil gelatinase-associated lipocalin (NGAL) were able to preserve their M2 phenotype. Nowadays, little is known about M2 macrophage effects in diabetic kidney disease (DKD). The aim of the study was to investigate the therapeutic effect of both bone marrow-derived M2 (BM-ÑM2) and Ñ-NGAL macrophages in the db/db mice. Seventeen-week-old mice with established DKD were divided into five treatment groups with their controls D+BM-ÑM2; D+Ñ-BM; D+Ñ-NGAL; D+Ñ-RAW; D+SHAM and non-diabetic (ND) (db/- and C57bl/6J) animals. We infused 1 × 106 macrophages twice, at baseline and 2 weeks thereafter. BM-ÑM2 did not show any therapeutic effect whereas Ñ-NGAL significantly reduced albuminuria and renal fibrosis. The Ñ-NGAL therapy increased the anti-inflammatory IL-10 and reduced some pro-inflammatory cytokines, reduced the proportion of M1 glomerular macrophages and podocyte loss and was associated with a significant decrease of renal TGF-ß1. Overall, our study provides evidence that Ñ-NGAL macrophage cell therapy has a therapeutic effect on DKD probably by modulation of the renal inflammatory response caused by the diabetic milieu.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Diabetes Mellitus Experimental
/
Nefropatias Diabéticas
/
Terapia Baseada em Transplante de Células e Tecidos
/
Lipocalina-2
/
Macrófagos
Idioma:
En
Revista:
J Cell Mol Med
Assunto da revista:
BIOLOGIA MOLECULAR
Ano de publicação:
2019
Tipo de documento:
Article
País de afiliação:
Espanha